Verastem Oncology priced a $250 million public stock offering on 14 October 2026, the same day it disclosed new clinical data for VS-7375 across three cancers and said FDA had aligned with the company on the design of a first-line Phase 3 trial in metastatic pancreatic cancer — the disease where the oral KRAS G12D inhibitor has shown its strongest responses so far.
The responses behind a $250 million bet
Figures from Verastem's 14 October 2026 investor update and SEC filing.
The afternoon pancreatic, lung and colorectal cancer met
Verastem Oncology held an investor event on the morning of 14 October 2026 to walk through updated results from TARGET-D 101, the Phase 1/2a dose-escalation trial of VS-7375 that has been dosing patients since June 2025. By afternoon the company had also priced its $250 million offering and disclosed that FDA had aligned with it on the design of TARGET-D 301, the registrational Phase 3 trial in previously untreated metastatic pancreatic cancer. President and CEO Dan Paterson had previewed the sequence two months earlier, on the company's second-quarter earnings call.
The pancreatic cohort is where the company's case is strongest: at the 900 mg dose, 9 of 22 previously treated patients had a confirmed response, a 41% rate, including one confirmed complete response. A narrower eight-patient second-line subgroup showed a 50% response rate — a number that reads better than the 41% figure but rests on half as many patients, a caveat Verastem's own materials do not obscure. The 600 mg NSCLC cohort reported 43% confirmed responses among 23 previously treated patients.
“We remain focused on advancing what we believe is a differentiated KRAS G12D inhibitor.” Dan Paterson, President and CEO, Verastem Oncology — 6 August 2026 second-quarter earnings call, previewing the October data
An ON/OFF switch for one mutation
VS-7375 targets KRAS G12D, a mutation found in roughly 42% of KRAS-driven pancreatic cancers — more than any other single KRAS variant in that disease. Verastem licensed the molecule from Shanghai-based GenFleet Therapeutics, where it is known as GFH375, selecting it as the company's lead pipeline asset in December 2023 over its earlier RAF/MEK and FAK programs; Verastem holds development and commercialization rights everywhere outside mainland China, Hong Kong, Macau and Taiwan. The company describes VS-7375 as a dual ON/OFF inhibitor: rather than locking onto the mutant protein in a single state, as the approved G12C drugs do, it is designed to block KRAS G12D in both its active and inactive conformations.
What VS-7375 has that G12C rivals don’t
Selective for one mutation
VS-7375 targets G12D specifically, the variant behind the largest single share of KRAS-mutant pancreatic cancer, rather than the broader RAS family some rivals pursue.
A switch, not just a block
The dual ON/OFF design is meant to hold the mutant protein inactive in both conformational states, a mechanism distinct from the single-state G12C inhibitors already on the market.
Already a marketed oncology company
Verastem isn't pre-revenue: AVMAPKI plus FAKZYNJA, approved in 2025 for KRAS-mutant ovarian cancer, generated $25.1 million in net product revenue in the second quarter of 2026 alone.
The biggest slice of pancreatic KRAS
Two FDA-approved drugs already treat KRAS G12C — Amgen's LUMAKRAS and Bristol Myers Squibb's KRAZATI — but G12D has no approved targeted therapy. Several companies are chasing it, including AstraZeneca, Astellas Pharma and Incyte, whose INCB161734 is in trials for untreated metastatic pancreatic cancer. The most advanced rival is Revolution Medicines, whose pan-RAS drug daraxonrasib (marketed in the EU as Rasonque) won FDA accelerated approval in August 2026 for second-line pancreatic cancer and a positive CHMP opinion two months later; its pivotal evidence spans G12D, G12V and G12R mutations rather than G12D alone, a broader net that could reach more patients but with less selectivity for any one of them.
$526 million today, $7.8 billion by 2034
$526M → $7.8B
The 7MM KRAS-inhibitor market, 2025 to 2034, as forecast by DelveInsight (October 2026).
Regulatory News outlook
We put the G12D-specific slice of that market — the population VS-7375, INCB161734 and Revolution Medicines' combination regimen are all chasing — at roughly $3.3 billion by 2034, assuming G12D keeps its current share of KRAS-mutated pancreatic disease.
How we got here: DelveInsight's $7.8 billion 2034 forecast covers all KRAS mutations; G12D accounts for about 42% of KRAS-mutated pancreatic cancer, so we apply that share directly: $7.8B × 0.42 ≈ $3.3B.
VS-7375 against the G12D field
| Product | Mechanism | Mutation | Status | Route |
|---|---|---|---|---|
| VS-7375 (Verastem) | Dual ON/OFF KRAS inhibitor | G12D-selective | Phase 2 registration-directed; Phase 3 planned YE 2026 | Oral |
| Daraxonrasib / Rasonque (Revolution Medicines) | Pan-RAS tri-complex inhibitor | G12D, G12V, G12R and others | FDA accelerated approval (Aug 2026); EU CHMP positive opinion (Oct 2026) | Oral |
| INCB161734 (Incyte) | G12D-selective inhibitor | G12D | Phase 1/2, untreated metastatic pancreatic cancer | Oral |
| Sotorasib / LUMAKRAS (Amgen) | KRAS G12C inhibitor | G12C only | FDA approved (2021) | Oral |
From each company's own labelling, announcements and public filings; not a clinical comparison.
From stem cells to a single mutation
Sixteen years, three pivots
- 2010
Verastem founded
Commenced operations in Needham, Massachusetts, built on cancer-stem-cell research from MIT and Whitehead Institute scientists Robert Weinberg, Eric Lander and Piyush Gupta.
- 2015
COMMAND trial halted
The Phase 3 COMMAND trial of defactinib, then a standalone FAK-inhibitor candidate for mesothelioma, stopped for lack of efficacy; Verastem cut about half its workforce and refocused its research.
- December 2023
VS-7375 licensed
Verastem licensed VS-7375 (as GFH375) from GenFleet Therapeutics and selected it as the company's lead pipeline program.
- May 2025
First FDA approval
Accelerated approval for AVMAPKI (avutometinib) plus FAKZYNJA (defactinib) in KRAS-mutant recurrent low-grade serous ovarian cancer, roughly two months ahead of its PDUFA date.
- June–July 2025
TARGET-D 101 begins; Fast Track granted
First patient dosed in the Phase 1/2a TARGET-D 101 trial; FDA granted Fast Track designation for VS-7375 in KRAS G12D-mutated pancreatic cancer the following month.
- 14 October 2026
$250M priced; Phase 3 design agreed
Verastem priced its public offering, disclosed multi-tumor TARGET-D 101 data and said FDA had aligned on the TARGET-D 301 Phase 3 design.
- Year-end 2026
TARGET-D 301 planned to open
The first-line pancreatic Phase 3 trial is targeted to begin enrollment, pending site activation and a final FDA-cleared protocol.
- 1 January 2027
CEO transition
Michael P. Bailey is set to succeed Dan Paterson as President and CEO, a transition announced in August 2026, unrelated to the October financing.
The trial that decides VS-7375 hasn't opened yet
Verastem's stock rose on the October news, but nothing in the readout is a registration-trial result. TARGET-D 101 is a dose-escalation study, not a pivotal one: its response rates come from small, single-arm cohorts without a control group, and the company's own disclosures note that the more striking 50% pancreatic figure rests on just eight patients, half of whom responded. The trial that will actually support an approval, TARGET-D 301, has not yet enrolled its first patient.
- Phase 3 start: TARGET-D 301, the first-line pancreatic trial, is planned to open by year-end 2026, pending site activation and a final FDA-cleared protocol.
- Offering mechanics: 30,937,500 shares at $8.00 plus pre-funded warrants for up to 312,503 additional shares; Jefferies, Guggenheim Securities and Cantor acted as joint book-running managers, with B. Riley Securities as lead manager.
- Leadership transition: President and CEO Dan Paterson is set to hand the role to Michael P. Bailey on 1 January 2027 — announced in August 2026, unrelated to the October financing.
- Still pending: overall survival data, a durability readout beyond the initial responses, and the final Phase 3 protocols for TARGET-D 302 (lung) and TARGET-D 303 (colorectal), both still in FDA discussions.
Regulatory News will update this page once TARGET-D 301 opens for enrollment, and when a trial registry update or FDA meeting record confirms the agreed design in full.
Sources & further reading
- Verastem, Inc., Prospectus Supplement (Form 424B5), public offering of common stock and pre-funded warrants, filed 14 October 2026. sec.gov
- BioPharma Dive, “Verastem's G12D pancreatic cancer drug shows early responses as it raises new cash,” 14 October 2026. biopharmadive.com
- OncLive, “VS-7375 Elicits Responses in KRAS G12D–Mutated Pancreatic Cancer,” 14 October 2026. onclive.com
- Mintz, “Mintz Advises Verastem Oncology's $250 Million Underwritten Offering,” October 2026. mintz.com
- Verastem Oncology, “Verastem Oncology Exercises Option to Early License VS-7375, an Oral KRAS G12D ON/OFF Inhibitor,” investor news release. investor.verastem.com
- Verastem Oncology, “Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates,” 6 August 2026. businesswire.com
- Verastem Oncology, “Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan,” August 2026. investor.verastem.com
- DelveInsight, “KRAS Inhibitors — Market Size, Target Population, Competitive Landscape and Forecast 2036,” October 2026. globenewswire.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did Verastem announce on 14 October 2026?
Verastem priced a $250 million underwritten public offering, the same day it disclosed new TARGET-D 101 clinical data for VS-7375 across pancreatic, lung and colorectal cancers and said FDA had aligned with the company on the design of a first-line Phase 3 pancreatic cancer trial, TARGET-D 301.
Has FDA approved VS-7375?
No. VS-7375 is an investigational oral KRAS G12D inhibitor in Phase 1/2a dose-escalation (TARGET-D 101) and Phase 2 registration-directed trials. No new drug application has been filed.
What did FDA agree to for the Phase 3 trial?
A three-arm design for previously untreated metastatic pancreatic cancer: VS-7375 at 900 mg with anti-EGFR therapy, VS-7375 with gemcitabine/nab-paclitaxel, or investigator's choice of gemcitabine/nab-paclitaxel or modified FOLFIRINOX, with progression-free survival and objective response rate as dual primary endpoints and overall survival as a secondary endpoint.
Is Verastem's approved drug the same as VS-7375?
No. AVMAPKI (avutometinib) plus FAKZYNJA (defactinib), FDA-approved in May 2025 for KRAS-mutant recurrent low-grade serous ovarian cancer, is a different, already-marketed combination. VS-7375 is a separate, unapproved KRAS G12D inhibitor licensed from GenFleet Therapeutics.
